Parent and Infant Inter(X)Action Intervention (PIXI)
Launched by RTI INTERNATIONAL · Feb 7, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The primary goal of the proposed project is to develop and test, through an iterative process, an intervention to address and support the development of infants with a rare neurogenetic condition (e.g., fragile X, Angelman, Prader-Willi, Dup15q, Phelan-McDermid, Rhett, Smith Magenis, Williams, Turner, Kleinfelter, Down syndromes, Duchenne muscular dystrophy) identified prior to emergence of symptoms. PiXI aims to utilize the foundational knowledge available around the development of and early intervention for at-risk infants to both understand the needs of and provide intervention services ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants 15 months of age or younger who have received a diagnosis which was not sought solely due to parental concerns about the infant (e.g. diagnosis due to prenatal or newborn screening, cascade testing following diagnosis of a family member).
- • English must be the primary language spoken in the home because all assessment measures and intervention protocol are in English.
- Exclusion Criteria:
- • - Infants may not be blind or have a severe hearing impairment as the intervention and assessments are not appropriate for these children.
About Rti International
RTI International is a leading nonprofit research institute dedicated to improving the human condition through innovative scientific research and technical assistance. With a strong focus on health and social science, RTI collaborates with various stakeholders, including government agencies, private organizations, and academic institutions, to advance knowledge and drive impactful solutions. The organization is recognized for its rigorous methodologies and commitment to ethical research practices, making it a trusted sponsor for clinical trials aimed at enhancing public health and advancing medical science. Through its comprehensive approach, RTI International contributes to the development of evidence-based strategies that address pressing health challenges globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Research Triangle Park, North Carolina, United States
Patients applied
Trial Officials
Anne Wheeler, PhD
Principal Investigator
RTI International
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials